Seborrhea - Pipeline Insight, 2024

This “Seborrhea - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Seborrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Seborrhea Understanding

Seborrhea: Overview

A chronic inflammatory disease of the skin characterized by the accumulation of scales of greasy skin. There may be yellow crusted plaques that are itchy. Seborrhea often affects the scalp. Other sites include the face, ears, eyebrows and eyelids, umbilicus, and genitalia, Seborrhea of the scalp is commonly known as dandruff. Seborrhea can be a primary or secondary disease. Primary Seborrhea is inherited and Secondary Seborrhea is more common; however the exact cause cannot always be determined.It is likely that a number of factors, such as hormones and stress, can cause it. A yeast-like organism plays an important role. Infants may get Seborrhea. Seborrhea also affects adults and elderly persons, and is more common in men than in women. Seborrhea occurs more frequently in persons with oily skin.

Seborrhea - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Seborrhea pipeline landscape is provided which includes the disease overview and Seborrhea treatment guidelines. The assessment part of the report embraces, in depth Seborrhea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Seborrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Seborrhea R&D. The therapies under development are focused on novel approaches to treat/improve Seborrhea.

Seborrhea Emerging Drugs Chapters

This segment of the Seborrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Seborrhea Emerging Drugs

ARQ154 (Topical Roflumilast Foam): Arcutis Biotherapeutics, Inc.

Roflumilast has been approved by the U.S. Food and Drug Administration (FDA) for systemic treatment to reduce the risk of exacerbations of chronic obstructive pulmonary disease (COPD) since 2011. Arcutis Biotherapeutics Inc. got positive topline data from its Phase 2 clinical trial evaluating ARQ-154 (topical roflumilast foam) as a potential treatment for seborrheic dermatitis. Topical roflumilast foam (ARQ-154) is a foam formulation of a highly potent and selective PDE4 inhibitor (roflumilast).

Seborrhea: Therapeutic Assessment

This segment of the report provides insights about the different Seborrhea drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Seborrhea

There are approx. 3+ key companies which are developing the therapies for Seborrhea. The companies which have their Seborrhea drug candidates in the most advanced stage, i.e. phase II include, Arcutis Biotherapeutics Inc.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

The Seborrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Seborrhea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Seborrhea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Seborrhea drugs.

• Seborrhea Report Insights
• Seborrhea Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
• Seborrhea Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

• Current Treatment Scenario and Emerging Therapies:How many companies are developing Seborrhea drugs?
• How many Seborrhea drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Seborrhea?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Seborrhea therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Seborrhea and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Arcutis Biotherapeutics
• Cutanea Life Sciences Inc.
• Vyome Therapeutics

Key Products

• ARQ-154
• VB-001
• CLS005